Composition for the treatment of progressive renal diseases
Described herein is an association of at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive antihypertensive agent and at least one antifibrotic agent for the management of progressive renal diseases including chronic kidney diseases (CKD) in domestic carnivores. Specifically, the application describes veterinarian compositions comprising such an association and the use thereof for the treatment of CKD conditions.
1. A method of treating a domestic animal for high blood pressure and/or progressive renal disease, the method comprising administering an association comprising at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive anti-hypertensive agent and at least one antifibrotic agent sufficient to induce a decrease in serum creatinine concentration in the domestic animal; wherein the association comprises a mixture of calcium carbonate and magnesium carbonate in the ratio of calcium carbonate to magnesium carbonate of between 3:1 and 4:1, and wherein the domestic animal is a cat.
2. The method of claim 1 , wherein the association is administered to the domestic animal once or twice daily.
3. A method of treating chronic kidney disease (CKD), chronic renal failure (CRF), chronic renal disease, kidney insufficiency, kidney failure or azotemia in a domestic animal, the method comprising administering an association comprising at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive anti-hypertensive agent and at least one antifibrotic agent sufficient to induce a decrease in serum creatinine concentration in the domestic animal; wherein the association comprises a mixture of calcium carbonate and magnesium carbonate in ratio of calcium carbonate to magnesium carbonate of between 3:1 and 4:1, and wherein the domestic animal is a cat.
4. The method of claim 3 , wherein the association is administered to the domestic animal once or twice daily.